Cardiff Oncology, Inc. (CRDF) Tops Q3 EPS by 6c

Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q3 EPS of ($0.22), $0.06 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $141 thousand versus the consensus estimate of $61.6 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.

You May Also Be Interested In

• Wolverine World Wide (WWW) Tops Q2 EPS by 2c; offers guidance
• X-Energy, Inc. (XE) Reports Q2 Loss of $0.15
• Birkenstock Holding (BIRK) Misses Q3 EPS by 2c; lifts guidance